JP6457386B2 - 抗−ｄｒ５ファミリー抗体、二重特異性又は多価の抗−ｄｒ５ファミリー抗体及びそれらの使用方法 - Google Patents

抗−ｄｒ５ファミリー抗体、二重特異性又は多価の抗−ｄｒ５ファミリー抗体及びそれらの使用方法 Download PDF

Info

Publication number
JP6457386B2
JP6457386B2 JP2015520954A JP2015520954A JP6457386B2 JP 6457386 B2 JP6457386 B2 JP 6457386B2 JP 2015520954 A JP2015520954 A JP 2015520954A JP 2015520954 A JP2015520954 A JP 2015520954A JP 6457386 B2 JP6457386 B2 JP 6457386B2
Authority
JP
Japan
Prior art keywords
seq
sequence
polypeptide
antibody
cdr1
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2015520954A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015527992A (ja
Inventor
ブリジット フェルナンド ベルモ−デスロシェ クローディーヌ
ブリジット フェルナンド ベルモ−デスロシェ クローディーヌ
フレデリック スビジェル オリビエ
フレデリック スビジェル オリビエ
フランソワーズ ジャンヌ−マリー ブルダン ローレンス
フランソワーズ ジャンヌ−マリー ブルダン ローレンス
Original Assignee
ゲンマブ ホールディング ベスローテン フェンノートシャップ
ゲンマブ ホールディング ベスローテン フェンノートシャップ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ゲンマブ ホールディング ベスローテン フェンノートシャップ, ゲンマブ ホールディング ベスローテン フェンノートシャップ filed Critical ゲンマブ ホールディング ベスローテン フェンノートシャップ
Publication of JP2015527992A publication Critical patent/JP2015527992A/ja
Application granted granted Critical
Publication of JP6457386B2 publication Critical patent/JP6457386B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Transplantation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2015520954A 2012-07-09 2013-07-09 抗−ｄｒ５ファミリー抗体、二重特異性又は多価の抗−ｄｒ５ファミリー抗体及びそれらの使用方法 Active JP6457386B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP12305821.6A EP2684896A1 (en) 2012-07-09 2012-07-09 Anti-DR5 family antibodies, bispecific or multivalent anti-DR5 family antibodies and methods of use thereof
EP12305821.6 2012-07-09
US201261669866P 2012-07-10 2012-07-10
US61/669866 2012-07-10
PCT/EP2013/064466 WO2014009358A1 (en) 2012-07-09 2013-07-09 Anti-dr5 family antibodies, bispecific or multivalent anti-dr5 family antibodies and methods of use thereof

Publications (2)

Publication Number Publication Date
JP2015527992A JP2015527992A (ja) 2015-09-24
JP6457386B2 true JP6457386B2 (ja) 2019-01-23

Family

ID=46514282

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015520954A Active JP6457386B2 (ja) 2012-07-09 2013-07-09 抗−ｄｒ５ファミリー抗体、二重特異性又は多価の抗−ｄｒ５ファミリー抗体及びそれらの使用方法

Country Status (15)

Country Link
US (4) US9611327B2 (cg-RX-API-DMAC7.html)
EP (3) EP2684896A1 (cg-RX-API-DMAC7.html)
JP (1) JP6457386B2 (cg-RX-API-DMAC7.html)
CN (1) CN104619725B (cg-RX-API-DMAC7.html)
BR (1) BR112015000449B1 (cg-RX-API-DMAC7.html)
CA (1) CA2878790C (cg-RX-API-DMAC7.html)
DK (1) DK2877491T3 (cg-RX-API-DMAC7.html)
ES (1) ES2727486T3 (cg-RX-API-DMAC7.html)
IL (2) IL236651B (cg-RX-API-DMAC7.html)
IN (1) IN2015DN00143A (cg-RX-API-DMAC7.html)
PL (1) PL2877491T3 (cg-RX-API-DMAC7.html)
PT (1) PT2877491T (cg-RX-API-DMAC7.html)
SG (2) SG10201700148UA (cg-RX-API-DMAC7.html)
SI (1) SI2877491T1 (cg-RX-API-DMAC7.html)
WO (1) WO2014009358A1 (cg-RX-API-DMAC7.html)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL308212A (en) 2015-01-20 2024-01-01 Igm Biosciences Inc Tumor necrosis factor-α receptor binding molecules and their uses
EP3048116A1 (en) 2015-01-23 2016-07-27 International-Drug-Development-Biotech Anti-dr5 antibodies with enhanced apoptosis potency
SG11201706024YA (en) * 2015-01-26 2017-08-30 Macrogenics Inc Multivalent molecules comprising dr5-binding domains
EP3112381A1 (en) * 2015-07-01 2017-01-04 FONDAZIONE IRCCS Istituto Nazionale dei Tumori Bispecific antibodies for use in cancer immunotherapy
SI3322734T1 (sl) 2015-07-16 2021-02-26 Inhibrx, Inc. Multivalentni in multispecifični DR5-vezavni fuzijski proteini
WO2017093447A1 (en) 2015-12-01 2017-06-08 Genmab B.V. Anti-death receptor antibodies and methods of use thereof
CN106397594B (zh) * 2016-10-25 2019-06-04 中国药科大学 一种全人源的抗人死亡受体5的激动剂单链抗体及应用
US20190276549A1 (en) 2016-11-01 2019-09-12 Genmab B.V. Polypeptide variants and uses thereof
EP3360898A1 (en) 2017-02-14 2018-08-15 Boehringer Ingelheim International GmbH Bispecific anti-tnf-related apoptosis-inducing ligand receptor 2 and anti-cadherin 17 binding molecules for the treatment of cancer
CA3053222A1 (en) 2017-02-10 2018-08-16 Genmab B.V. Polypeptide variants and uses thereof
KR101926834B1 (ko) * 2017-03-21 2018-12-07 동아에스티 주식회사 항-dr5 항체 및 그의 용도
JP2020522543A (ja) 2017-06-07 2020-07-30 ゲンマブ ビー．ブイ． 変異ＩｇＧ六量体に基づく治療用抗体
JP2021510740A (ja) 2018-01-24 2021-04-30 ゲンマブ ビー．ブイ． ポリペプチド変種およびそれらの用途
EP3759229A4 (en) * 2018-02-26 2021-12-29 IGM Biosciences Inc. Use of a multimeric anti-dr5 binding molecule in combination with a chemotherapeutic agent for treating cancer
WO2019211472A1 (en) 2018-05-03 2019-11-07 Genmab B.V. Antibody variant combinations and uses thereof
WO2020136218A1 (en) * 2018-12-26 2020-07-02 Imcheck Therapeutics Sas Btn3a binding proteins and uses thereof
WO2020225456A1 (en) 2019-05-09 2020-11-12 Genmab B.V. Dosage regimens for a combination of anti-dr5 antibodies for use in treating cancer
EP4055046A1 (en) 2019-11-06 2022-09-14 Genmab B.V. Antibody variant combinations and uses thereof
US20230293680A1 (en) 2020-07-23 2023-09-21 Genmab B.V. A composition of anti-dr5 antibodies and an immunomodulatory imide drug for use in treating multiple myeloma
KR20240170601A (ko) * 2022-03-02 2024-12-03 월든 바이오사이언시즈, 인크. 신규한 가용성 유로키나제 플라스미노겐 활성화제 수용체(supar) 결합 분자 및 이의 용도

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4342566A (en) 1980-02-22 1982-08-03 Scripps Clinic & Research Foundation Solid phase anti-C3 assay for detection of immune complexes
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5204244A (en) 1987-10-27 1993-04-20 Oncogen Production of chimeric antibodies by homologous recombination
US5202238A (en) 1987-10-27 1993-04-13 Oncogen Production of chimeric antibodies by homologous recombination
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US6284236B1 (en) 1995-06-29 2001-09-04 Immunex Corporation Cytokine that induces apoptosis
CA2249206A1 (en) 1996-04-01 1997-10-09 Genentech, Inc. Apo-2li and apo-3 apoptosis polypeptides
DE69837806T3 (de) 1997-01-28 2012-01-05 Human Genome Sciences, Inc. "death-domain"-enthaltender rezeptor 4 (dr4), ein mitglied der tnf-rezeptor superfamilie, welcher an trail (apo-2l) bindet
US20050233958A1 (en) 1997-03-17 2005-10-20 Human Genome Sciences, Inc. Death domain containing receptor 5
US6872568B1 (en) 1997-03-17 2005-03-29 Human Genome Sciences, Inc. Death domain containing receptor 5 antibodies
DE69939732D1 (de) * 1998-01-15 2008-11-27 Genentech Inc Apo-2 ligand
WO1999037791A1 (en) 1998-01-23 1999-07-29 Vlaams Interuniversitair Instituut Voor Biotechnologie Multipurpose antibody derivatives
EP1068241B1 (en) 1998-04-02 2007-10-10 Genentech, Inc. Antibody variants and fragments thereof
EP1192185B1 (en) 1999-06-09 2006-06-21 Genentech, Inc. Apo-2L RECEPTOR AGONIST AND CPT-11 SYNERGISM
US6444640B1 (en) 1999-09-30 2002-09-03 Ludwig Institute For Cancer Research Compositions of trail and DNA damaging drugs and uses thereof
US7279160B2 (en) 2000-05-02 2007-10-09 The Uab Research Foundation Combinations of DR5 antibodies and other therapeutic agents
GB0020442D0 (en) 2000-08-18 2000-10-04 Nokia Networks Oy Data transmission protocol
US20020155109A1 (en) 2001-04-20 2002-10-24 Lynch David H. Bispecific antibodies that bind TRAIL-R1 and TRAIL-R2
KR100942393B1 (ko) 2001-05-25 2010-02-17 휴먼 게놈 사이언시즈, 인코포레이티드 Ｔｒａｉｌ 수용체에 면역특이적으로 결합하는 항체
ATE433996T1 (de) 2001-07-03 2009-07-15 Genentech Inc Humane dr4-antikörper und deren anwendungen
KR20070010046A (ko) * 2004-04-06 2007-01-19 제넨테크, 인크. Ｄｒ5 항체 및 그의 용도
AU2005335714B2 (en) 2004-11-10 2012-07-26 Macrogenics, Inc. Engineering Fc antibody regions to confer effector function
CA2599265A1 (en) 2005-02-28 2006-09-08 Centocor, Inc. Heterodimeric protein binding compositions
EP1999470A4 (en) 2006-03-10 2009-08-19 Macrogenics Inc IDENTIFICATION AND GENETIC MODIFICATION OF ANTIBODIES WITH HEAVY CHAINS OF VARIANTS AND METHODS OF USE THEREOF
KR100847010B1 (ko) 2006-07-05 2008-07-17 아주대학교산학협력단 세포사멸 수용체 5 (ｄｒ5)에 특이적으로 결합하는 항체 및이를 포함하는 암 예방 또는 치료용 조성물
WO2009002947A2 (en) 2007-06-22 2008-12-31 Affymax, Inc. Compounds and peptides that bind the trail receptor
UA117901C2 (uk) * 2011-07-06 2018-10-25 Ґенмаб Б.В. Спосіб посилення ефекторної функції вихідного поліпептиду, його варіанти та їх застосування

Also Published As

Publication number Publication date
CN104619725B (zh) 2019-04-23
PT2877491T (pt) 2019-06-07
SG10201700148UA (en) 2017-02-27
CA2878790C (en) 2023-09-26
US20170260281A1 (en) 2017-09-14
EP2877491A1 (en) 2015-06-03
WO2014009358A1 (en) 2014-01-16
US20240141057A1 (en) 2024-05-02
BR112015000449A2 (cg-RX-API-DMAC7.html) 2017-08-15
IL269527B (en) 2021-12-01
IN2015DN00143A (cg-RX-API-DMAC7.html) 2015-06-12
US10647774B2 (en) 2020-05-12
EP3575323B1 (en) 2024-09-11
SI2877491T1 (sl) 2019-08-30
IL236651A0 (en) 2015-02-26
CN104619725A (zh) 2015-05-13
US20150139997A1 (en) 2015-05-21
DK2877491T3 (da) 2019-06-03
IL269527A (en) 2019-11-28
SG11201500177PA (en) 2015-03-30
JP2015527992A (ja) 2015-09-24
EP3575323A1 (en) 2019-12-04
EP2877491B1 (en) 2019-02-27
IL236651B (en) 2019-10-31
US9611327B2 (en) 2017-04-04
EP2684896A1 (en) 2014-01-15
CA2878790A1 (en) 2014-01-16
PL2877491T3 (pl) 2020-01-31
BR112015000449B1 (pt) 2022-12-20
ES2727486T3 (es) 2019-10-16
US20200332016A1 (en) 2020-10-22
HK1211044A1 (en) 2016-05-13

Similar Documents

Publication Publication Date Title
US20240141057A1 (en) Anti-dr5 family antibodies, bispecific or multivalent anti-dr5 family antibodies and methods of use thereof
CN113645996B (zh) 抗claudin 18抗体及其使用方法
CN114269782B (zh) 抗tigit抗体及其应用
CA3207791A1 (en) Anti-cd112r antibody and use thereof
WO2023143343A1 (en) Anti-her2/trop2 antibodies and uses thereof
WO2024184812A1 (en) Anti-cldn6 antibodies and methods of use
TW202428608A (zh) 抗b7h3抗體以及其使用方法
JP2023534683A (ja) 抗ｃｌｄｎ－１８．２抗体及びその用途
US12077597B2 (en) Anti-CD5 antibodies and methods of use thereof
CN113164601B (zh) 一种分离的抗原结合蛋白及其用途
TW202430568A (zh) 抗b7h3抗體以及其使用方法
CN120917047A (zh) 抗cldn6和抗cd3多特异性抗体及其使用方法
HK1211044B (en) Anti-dr5 family antibodies, bispecific or multivalent anti-dr5 family antibodies and methods of use thereof
CN121057749A (zh) 抗cd3多特异性抗体和使用方法
WO2024184810A1 (en) Anti-cldn6 and anti-cd3 multispecific antibodies and methods of use
WO2024184811A1 (en) Anti-cd3 multispecific antibodies and methods of use
CN120813606A (zh) 抗cldn6抗体和使用方法
HK40064186A (en) Anti-claudin 18 antibodies and methods of use thereof
HK40074321B (zh) 使用抗ox40抗体与抗tim3抗体的组合治疗癌症的方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150317

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20160120

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20160120

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160704

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170328

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170627

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170928

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180123

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180420

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180720

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180925

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181108

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20181120

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20181220

R150 Certificate of patent or registration of utility model

Ref document number: 6457386

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250